IP Library Granted Patent US 9,844,641
Granted Patent B2
US 9,844,641 · App. 15/274,809 · Granted Dec 19, 2017

Systems, devices and methods for performing medical procedures in the intestine

Inventors: Harith Rajagopalan (Wellesley Hills, MA); Jay Caplan (Belmont, MA); Craig M. Gardner (Belmont, MA); J. Christopher Flaherty (Auburndale, FL)
Assignee: FRACTYL LABORATORIES, INC.
A61M25/00A61B5/0084A61B5/4255A61B5/4836A61B5/6852A61B5/6885A61B17/00234A61B18/02A61B18/082A61B18/1492A61B18/1815A61F5/0069A61F5/0079A61M25/04A61N7/00A61B5/0066A61B5/055A61B17/00491A61B17/0218A61B18/06A61B18/24A61B2017/00004A61B2017/00022A61B2017/00199A61B2017/00818A61B2018/00005A61B2018/00011A61B2018/00017A61B2018/0022A61B2018/00029A61B2018/00041A61B2018/00255A61B2018/00285A61B2018/00291A61B2018/00494A61B2018/00559A61B2018/00577A61B2018/00642A61B2018/00672A61B2018/00678A61B2018/00744A61B2018/00791A61B2018/00809A61B2018/00815A61B2018/00821A61B2018/00839A61B2018/00863A61B2018/00875A61B2018/00982A61B2018/0212A61B2018/046A61B2018/1861A61B2090/395A61B2090/3908A61B2090/3933A61B2218/002A61B2505/05A61B2560/0431A61B2562/227A61M2210/1053A61M2210/1057A61M2210/1071A61M2210/1408A61N7/022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,844,641
App. No.
15/274,809
Granted
Dec 19, 2017
Kind
B2
Abstract

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element. The catheter is introduced into the patient, and target tissue is treated with the at least one treatment element. The target tissue comprises mucosal tissue of the small intestine, and the medical procedure can be configured to treat polycystic ovarian syndrome (PCOS).

Claims (38)

1. A method for performing a medical procedure in an intestine of a patient, comprising:

selecting a patient diagnosed as having polycystic ovarian syndrome;

providing a system comprising:

a catheter for insertion into the intestine, the catheter comprising:

an elongate shaft comprising a distal portion; and

a functional assembly positioned on the shaft distal portion and comprising at least one treatment element;

introducing the catheter into the patient diagnosed as having polycystic ovarian syndrome; and

treating target tissue with the at least one treatment element, wherein the target tissue comprises mucosal tissue of the patient's small intestine;

wherein the medical procedure is configured to treat polycystic ovarian syndrome.

2. The method according to claim 1 , wherein the medical procedure is further configured to treat insulin resistance.

3. The method according to claim 1 , wherein the medical procedure is further configured to treat a disease or disorder selected from the group consisting of: Type 2 diabetes; Type 1 diabetes; “Double diabetes”; gestational diabetes; hyperglycemia; pre-diabetes; impaired glucose tolerance; insulin resistance; and combinations thereof.

4. The method according to claim 1 , wherein the system further comprises a console operably attached to the functional assembly, and wherein the console comprises one or more variable console parameters used to control the functional assembly.

5. The method according to claim 4 , wherein the system further comprises at least one sensor constructed and arranged to produce a sensor signal, and wherein the method further comprises adjusting at least one variable console parameter based on the sensor signal.

6. The method according to claim 5 , wherein the console is configured to perform closed-loop energy delivery to the functional assembly based on the sensor signal.

7. The method according to claim 1 , wherein treating target tissue modifies at least one of nutrient absorption by the target tissue, hormonal signaling from the target tissue, or secretions of the target tissue.

8. The method according to claim 1 , wherein treating target tissue comprises treating mucosal tissue within 15 cm of the patient's ampulla of Vater.

9. The method according to claim 1 , wherein the method comprises avoiding treating tissue between a first location proximate the patient's ampulla of Vater and a second location 0.5 cm distal to the patient's ampulla of Vater.

10. The method according to claim 1 , wherein at least 6 cm of length of the patient's duodenum are treated.

11. The method according to claim 1 , wherein at least 9 cm of length of the patient's duodenum are treated.

12. The method according to claim 1 , wherein treating target tissue comprises treating at least a first axial segment and a second axial segment of the intestine.

13. The method according to claim 1 , wherein treating target tissue comprises treating between two and six axial segments of the intestine to treat at least 6 cm of axial length of intestine.

14. The method according to claim 1 , wherein treating target tissue comprises treating an amount of tissue that is based on the severity of the patient's PCOS.

15. The method according to claim 1 , further comprising identifying non-target tissue, wherein the non-target tissue is identified by marking tissue selected from the group consisting of: ampulla of Vater; tissue proximate the ampulla of Vater; pylorus; tissue proximate the pylorus; and combinations thereof.

16. The method according to claim 1 , wherein treating target tissue comprises a series of tissue ablation steps, each comprising ablation of an axial length of intestinal tissue, wherein each ablation step is preceded by a tissue expansion step.

17. The method according to claim 16 , further comprising preventing axial motion of the functional assembly between the tissue expansion and the tissue treatment steps.

18. The method according to claim 16 , further comprising applying vacuum to tissue during the tissue expansion step.

19. The method according to claim 1 , wherein treating target tissue comprises a series of tissue ablation steps, each ablation step comprising ablation of an axial length of intestinal tissue, wherein each ablation step is followed by a tissue neutralizing step.

20. The method according to claim 19 , wherein each ablation step comprises a heat ablation of tissue and each neutralizing step comprises a cooling of tissue.

21. The method according to claim 19 , further comprising performing a separate tissue neutralizing step prior to each ablation step.

22. The method according to claim 21 , wherein each ablation step comprises a heat ablation of tissue and each separate neutralizing step comprises a cooling of tissue.

23. The method according to claim 1 , further comprising maintaining the functional assembly at or below a target diameter.

24. The method according to claim 1 , further comprising maintaining the functional assembly at or below a target pressure.

25. The method according to claim 1 , further comprising maintaining the functional assembly at or below a target volume.

26. The method according to claim 1 , further comprising delivering an anti-peristaltic agent.

27. The method according to claim 1 , further comprising modifying a pressure of a segment of a segment of intestine that is proximate the target tissue being treated.

28. The method according to claim 1 , wherein the functional assembly includes a tissue contacting portion comprising a surface area between 500 mm2 and 3500 mm2.

29. The method according to claim 1 , where the functional assembly comprises an expanded diameter between 19 mm and 28 mm.

30. The method according to claim 1 , wherein the catheter further comprises a fluid removal port configured to remove fluid from a segment of the intestine.

Assignments (3)
SECURITY INTEREST Recorded Sep 7, 2023
From: FRACTYL HEALTH, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC
Reel/Frame 064840/0561 →
CHANGE OF NAME Recorded Oct 4, 2021
From: FRACTYL LABORATORIES, INC.
To: FRACTYL HEALTH, INC.
Reel/Frame 057725/0392 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2016
From: RAJAGOPALAN, HARITH; CAPLAN, JAY; GARDNER, CRAIG M.; FLAHERTY, J. CHRISTOPHER
To: FRACTYL LABORATORIES, INC.
Reel/Frame 040992/0326 →
Continuity (6)
Continuation In Part PCTUS2016040512 · Jun 30, 2016
Continuation In Part PCTUS2015040775 · Jul 16, 2015
Provisional Application 62187594 · Jul 1, 2015
Provisional Application 62025307 · Jul 16, 2014
Provisional Application 62273015 · Dec 30, 2015
Related Publication 20170014596A1 · Jan 19, 2017